Brady Lee Stein

Grants

Grants per year 2011 2011 2012 2013 2015 2018 2019 2021 2024

• 7 Active
• 12 Finished

Grants per year

Search results

• Active

  Prot #CPI 0610-04: A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (MANIFEST-2)

  Stein, B. L.

  Novella Clinical, LLC, Constellation Pharmaceuticals, Inc.

  7/26/21 → 7/26/24

  Project: Research project

• Prot #M19-753: A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination with Ruxolitinib in Myeloproliferative Neoplasm Subjects

  Stein, B. L.

  AbbVie Inc.

  6/18/21 → 6/18/22

  Project: Research project

• Targeting Plek2 for the treatment of myeloproliferative neoplasms

  Ji, P. & Stein, B. L.

  Leukemia & Lymphoma Society

  7/1/19 → 6/30/22

  Project: Research project

• Prot #KRT-232-101: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post-PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor

  Stein, B. L.

  PRA Health Sciences, Kartos Therapeutics, Inc.

  4/15/19 → 4/15/23

  Project: Research project

• Prot #0610-02: A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients wi

  Stein, B. L.

  Parexel, Constellation Pharmaceuticals, Inc.

  10/2/18 → 10/2/24

  Project: Research project

• Prot #INCB-MA-MF-401: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy

  Stein, B. L.

  Syneos Health, Inc., Incyte Corporation

  6/12/18 → 6/12/24

  Project: Research project

• Prot #PAC203: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib

  Stein, B. L.

  PSI Pharma Support America Inc., CTI BioPharma Corp.

  10/25/17 → 10/25/23

  Project: Research project

• Finished

  Prot #KRT-232-102: A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

  Stein, B. L.

  PRA Health Sciences, Kartos Therapeutics, Inc.

  4/15/19 → 4/15/22

  Project: Research project

• Anti-PDL1 therapy for patients with Myelofibrosis

  Stein, B. L., Wainwright, D. A. & Wolniak, K. L.

  MPN Research Foundation and the Leukemia & Lymphoma Society

  8/1/16 → 5/22/17

  Project: Research project

  • atezolizumab 100%
  • Primary Myelofibrosis 86%
  • Neoplasms 24%
  • Extramedullary Hematopoiesis 18%
  • Janus Kinase Inhibitors 17%

• Prot #INCB-MA-PV-401: Prospective, Non-Interventional Study of Disease Progression and Treatment of Patients with Polycythemia Vera in United States Academic or Community Clinical Practices

  Stein, B. L.

  United BioSource LLC, Incyte Corporation

  6/11/15 → 6/11/20

  Project: Research project

• Prot #PAC326: A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

  Stein, B. L.

  CTI BioPharma Corp.

  1/6/15 → 1/6/18

  Project: Research project

• MLN8237, an Aurora A kinase inhibitor, for treatment of myeloid malignancies

  Crispino, J. D., Altman, J. K., Giles, F. J., Stein, B. L. & Wen, Q.

  Leukemia & Lymphoma Society

  10/1/14 → 8/31/19

  Project: Research project

  • Aurora Kinase A 100%
  • MLN 8237 99%
  • Leukemia, Megakaryoblastic, Acute 88%
  • Primary Myelofibrosis 70%
  • Neoplasms 21%

• Development of an oral anti-fibrotic drug for patients with myelofibrosis

  Stein, B. L.

  Leukemia & Lymphoma Society

  10/1/13 → 9/30/16

  Project: Research project

  • Primary Myelofibrosis 100%
  • Hepatocyte Growth Factor 50%
  • Captopril 25%
  • Pharmaceutical Preparations 18%
  • INCB018424 16%

• Prot #INCB 18424-357: Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes

  Stein, B. L.

  PharmaNet, Inc., Incyte Corporation

  1/17/13 → 1/17/19

  Project: Research project

• Prot #NS-018-101: A Phase 1/2, Open-label, Dose-escalation, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofib

  Stein, B. L.

  Parexel, NS Pharma, Inc.

  12/13/12 → 12/31/21

  Project: Research project

• Prot# NU MSK 11H01: Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients with Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

  Altman, J. K., Frankfurt, O., Stein, B. L. & Winter, J. N.

  Memorial Sloan-Kettering Cancer Center

  6/15/12 → 6/15/18

  Project: Research project

• Prot# INCB 18424-258: An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of 50x

  Stein, B. L.

  PPD Development, Incyte Corporation

  11/1/11 → 11/1/17

  Project: Research project

• Prot#CINC424B2301: Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst available care (The RESPONSE Trial)

  Stein, B. L.

  Parexel, Incyte Corporation

  9/23/11 → 9/23/17

  Project: Research project

• The Role of Tissue Factor and PAI-1 in Thrombosis and Myelofibrosis in the Myeloproliferative Neoplasms

  Stein, B. L.

  American Cancer Society

  1/1/11 → 12/31/11

  Project: Research project